160885-18-7Relevant academic research and scientific papers
NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
-
Paragraph 0646, (2013/03/26)
The present invention provides a novel compound having a superior activity as an ERR-alpha modulator and useful as an agent for the prophylaxis or treatment of ERR-alpha associated diseases. The present invention relates to a compound represented by the formula (1) wherein each symbol is as defined in the specification, or a salt thereof
Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the P2′ and P3′ side chains
Davies, Stephen J.,Ayscough, Andrew P.,Beckett, R. Paul,Clements, John M.,Doel, Sheila,Pratt, Lisa M.,Spavold, Zoe M.,Thomas, S. Wayne,Whittaker, Mark
, p. 2715 - 2718 (2007/10/03)
Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to both the P2′ and P3′ side chains. Enzyme inhibition and antibacterial activity data revealed that a variety of substituents are tolerated at the P2′ and P3′ positions of the inhibitor backbone. The data from this study highlights the potential for modification at the P2′ and P3′ positions to optimise the physicochemical properties.
Reaction of Trimethylsilylamines with N-Cbz-L-Serine-β-Lactone: A Convenient Route to Optically Pure β-Amino-L-alanine Derivatives
Ratemi, Elaref S.,Vederas, John C.
, p. 7605 - 7608 (2007/10/02)
Trimethylsilylamines, Me3Si-NR2, react with N-Cbz-L-serine-β-lactone in acetonitrile primarily by alkyl oxygen cleavage of the lactone ring to give optically pure N-Cbz-β-amino-L-alanine derivatives in good yields.Use of halogenated sovents such as chloro
